Shots: The agreement is focused on development of needle-free and solid-dose formulation for Shigella flexneri 2a artificial Invaplex (Sfl2a InvaplexAR) vaccine using Enesi Pharma’s ImplaVax technology WRAIR will examine biochemical integrity and immunogenicity of the solid-dose product in Shigella disease models Shigella infection (shigellosis) is a communicable form of bacterial diarrheal disease and is responsible […]Read More
